FIMI recently met with major investment institutions to test the feasibility of selling its holding in G1, formerly G4S, on the TASE.
Teva's Ajovy may have been rejected by Express Scripts for reimbursement but other US health insurers will accept it, say the analysts.
An approved urban building plan that applies to the entire site provides for construction of a 22-floor tower.
Teva fell sharply after a reimbursement snub as energy stocks exacerbated losses on the market.
The Israeli stem cell cancer therapy developer will hold the offering at a company valuation of $275 million.
Express Scripts has endorsed coverage of competing migraine drugs made by Amgen and Eli Lilly.
Under an agreement between the bank and IDB, first refusal rights will expire if there is no deal by November 11.
The Australian Securities Exchange has attracted 18 early-stage Israeli high-tech companies.
MakeMereach is a platform that enables agencies and advertisers to fully optimize their social campaigns.
The $100 million fund will invest in early stage insurtech startups.
The Singapore investment company is acquiring the Tel Aviv-based cybersecurity consulting startup.
Many analysts including Goldman Sachs do not see an interest rate hike in Israel this year.
The Greek energy exploration company's shares will be included in the Tel Aviv 90 Index; it will not issue new shares.
The bank is believed to be considering the sale, in view of the recent rise in Clal Insurance's share price.
Ashtrom will construct two office and commercial towers on the Bnei Brak site it owns jointly with Dan Bus Company.
The El Al board of directors approved the new labor agreement two weeks before new flight time limitation regulations are scheduled to take effect.
The Israeli hotel chain will rent and manage The Midland for 35 years.
The shareholders place the blame for the cancellation squarely on the Second Broadcasting Authority.
"No fault was found in the company's behavior and that of its executives in these areas."
BOL produces and markets cannabis for the Israeli market.
Non-banking companies will be able raise up to NIS 20 billion.
The US Court of Appeals for the Federal Circuit upheld a 2017 decision by a Delaware court canceling four patents on the 40 mg version of Teva's blockbuster multiple sclerosis treatment.
The price is $60 per tonne higher than in Israel Chemicals' previous contracts with Chinese customers.
The Ministry of Foreign affairs is adamant that it will stop employing flight security personnel overseas in January.
The Israeli solar energy company is acquiring a 75% stake in the Korean lithium-ion battery provider.
The beta trial of the Israeli company's app will begin in the coming weeks,
The companies have entered into a clinical trial collaboration to evaluate Compugen’s COM701 with BMS's PD-1 immune checkpoint inhibitor Opdivo, in patients with advanced solid tumors.
If the FDA approves CT-P10 for marketing, this will be the first biosimilar generic version of Rituxan.
President Donald Trump's criticism of US Fed policy puts into question its plan for four more rate hikes by the end of 2019.
The Tel Aviv Stock Exchange is also sharply down after President Trump criticized the US Fed's interest rate hikes.
US based Imperva was founded by three Israelis and has offices in Tel Aviv and Rehovot.
Teva loses another Copaxone patents case